Modulation of the cAMP signaling pathway after traumatic brain injury

Coleen M Atkins, Anthony A. Oliva, Ofelia F. Alonso, Damien D Pearse, Helen Bramlett, W. Dalton Dietrich

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Traumatic brain injury (TBI) results in both focal and diffuse brain pathologies that are exacerbated by the inflammatory response and progress from hours to days after the initial injury. Using a clinically relevant model of TBI, the parasagittal fluid-percussion brain injury (FPI) model, we found injury-induced impairments in the cyclic AMP (cAMP) signaling pathway. Levels of cAMP were depressed in the ipsilateral parietal cortex and hippocampus, as well as activation of its downstream target, protein kinase A, from 15 min to 48 h after moderate FPI. To determine if preventing hydrolysis of cAMP by administration of a phosphodiesterase (PDE) IV inhibitor would improve outcome after TBI, we treated animals intraperitoneally with rolipram (0.3 or 3.0 mg/kg) 30 min prior to TBI, and then once per day for 3 days. Rolipram treatment restored cAMP to sham levels and significantly reduced cortical contusion volume and improved neuronal cell survival in the parietal cortex and CA3 region of the hippocampus. Traumatic axonal injury, characterized by β-amyloid precursor protein deposits in the external capsule, was also significantly reduced in rolipram-treated animals. Furthermore, levels of the pro-inflammatory cytokines, interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), were significantly decreased with rolipram treatment. These results demonstrate that the cAMP-PKA signaling cascade is downregulated after TBI, and that treatment with a PDE IV inhibitor improves histopathological outcome and decreases inflammation after TBI.

Original languageEnglish
Pages (from-to)145-158
Number of pages14
JournalExperimental Neurology
Volume208
Issue number1
DOIs
StatePublished - Nov 1 2007

Fingerprint

Cyclic AMP
Rolipram
Type 4 Cyclic Nucleotide Phosphodiesterase
Percussion
Parietal Lobe
Phosphodiesterase Inhibitors
Brain Injuries
Hippocampus
Wounds and Injuries
Amyloid beta-Protein Precursor
Cyclic AMP-Dependent Protein Kinases
Interleukin-1
Traumatic Brain Injury
Cell Survival
Hydrolysis
Down-Regulation
Tumor Necrosis Factor-alpha
Pathology
Cytokines
Inflammation

Keywords

  • cAMP
  • Fluid-percussion
  • Inflammation
  • Interleukin-1β
  • Phosphodiesterase
  • PKA
  • Rolipram
  • TBI
  • TNF-α
  • Traumatic brain injury

ASJC Scopus subject areas

  • Neurology
  • Neuroscience(all)

Cite this

Modulation of the cAMP signaling pathway after traumatic brain injury. / Atkins, Coleen M; Oliva, Anthony A.; Alonso, Ofelia F.; Pearse, Damien D; Bramlett, Helen; Dalton Dietrich, W.

In: Experimental Neurology, Vol. 208, No. 1, 01.11.2007, p. 145-158.

Research output: Contribution to journalArticle

@article{ab0d4164fa8e4938b118bb55f1ea952e,
title = "Modulation of the cAMP signaling pathway after traumatic brain injury",
abstract = "Traumatic brain injury (TBI) results in both focal and diffuse brain pathologies that are exacerbated by the inflammatory response and progress from hours to days after the initial injury. Using a clinically relevant model of TBI, the parasagittal fluid-percussion brain injury (FPI) model, we found injury-induced impairments in the cyclic AMP (cAMP) signaling pathway. Levels of cAMP were depressed in the ipsilateral parietal cortex and hippocampus, as well as activation of its downstream target, protein kinase A, from 15 min to 48 h after moderate FPI. To determine if preventing hydrolysis of cAMP by administration of a phosphodiesterase (PDE) IV inhibitor would improve outcome after TBI, we treated animals intraperitoneally with rolipram (0.3 or 3.0 mg/kg) 30 min prior to TBI, and then once per day for 3 days. Rolipram treatment restored cAMP to sham levels and significantly reduced cortical contusion volume and improved neuronal cell survival in the parietal cortex and CA3 region of the hippocampus. Traumatic axonal injury, characterized by β-amyloid precursor protein deposits in the external capsule, was also significantly reduced in rolipram-treated animals. Furthermore, levels of the pro-inflammatory cytokines, interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), were significantly decreased with rolipram treatment. These results demonstrate that the cAMP-PKA signaling cascade is downregulated after TBI, and that treatment with a PDE IV inhibitor improves histopathological outcome and decreases inflammation after TBI.",
keywords = "cAMP, Fluid-percussion, Inflammation, Interleukin-1β, Phosphodiesterase, PKA, Rolipram, TBI, TNF-α, Traumatic brain injury",
author = "Atkins, {Coleen M} and Oliva, {Anthony A.} and Alonso, {Ofelia F.} and Pearse, {Damien D} and Helen Bramlett and {Dalton Dietrich}, W.",
year = "2007",
month = "11",
day = "1",
doi = "10.1016/j.expneurol.2007.08.011",
language = "English",
volume = "208",
pages = "145--158",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Modulation of the cAMP signaling pathway after traumatic brain injury

AU - Atkins, Coleen M

AU - Oliva, Anthony A.

AU - Alonso, Ofelia F.

AU - Pearse, Damien D

AU - Bramlett, Helen

AU - Dalton Dietrich, W.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Traumatic brain injury (TBI) results in both focal and diffuse brain pathologies that are exacerbated by the inflammatory response and progress from hours to days after the initial injury. Using a clinically relevant model of TBI, the parasagittal fluid-percussion brain injury (FPI) model, we found injury-induced impairments in the cyclic AMP (cAMP) signaling pathway. Levels of cAMP were depressed in the ipsilateral parietal cortex and hippocampus, as well as activation of its downstream target, protein kinase A, from 15 min to 48 h after moderate FPI. To determine if preventing hydrolysis of cAMP by administration of a phosphodiesterase (PDE) IV inhibitor would improve outcome after TBI, we treated animals intraperitoneally with rolipram (0.3 or 3.0 mg/kg) 30 min prior to TBI, and then once per day for 3 days. Rolipram treatment restored cAMP to sham levels and significantly reduced cortical contusion volume and improved neuronal cell survival in the parietal cortex and CA3 region of the hippocampus. Traumatic axonal injury, characterized by β-amyloid precursor protein deposits in the external capsule, was also significantly reduced in rolipram-treated animals. Furthermore, levels of the pro-inflammatory cytokines, interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), were significantly decreased with rolipram treatment. These results demonstrate that the cAMP-PKA signaling cascade is downregulated after TBI, and that treatment with a PDE IV inhibitor improves histopathological outcome and decreases inflammation after TBI.

AB - Traumatic brain injury (TBI) results in both focal and diffuse brain pathologies that are exacerbated by the inflammatory response and progress from hours to days after the initial injury. Using a clinically relevant model of TBI, the parasagittal fluid-percussion brain injury (FPI) model, we found injury-induced impairments in the cyclic AMP (cAMP) signaling pathway. Levels of cAMP were depressed in the ipsilateral parietal cortex and hippocampus, as well as activation of its downstream target, protein kinase A, from 15 min to 48 h after moderate FPI. To determine if preventing hydrolysis of cAMP by administration of a phosphodiesterase (PDE) IV inhibitor would improve outcome after TBI, we treated animals intraperitoneally with rolipram (0.3 or 3.0 mg/kg) 30 min prior to TBI, and then once per day for 3 days. Rolipram treatment restored cAMP to sham levels and significantly reduced cortical contusion volume and improved neuronal cell survival in the parietal cortex and CA3 region of the hippocampus. Traumatic axonal injury, characterized by β-amyloid precursor protein deposits in the external capsule, was also significantly reduced in rolipram-treated animals. Furthermore, levels of the pro-inflammatory cytokines, interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), were significantly decreased with rolipram treatment. These results demonstrate that the cAMP-PKA signaling cascade is downregulated after TBI, and that treatment with a PDE IV inhibitor improves histopathological outcome and decreases inflammation after TBI.

KW - cAMP

KW - Fluid-percussion

KW - Inflammation

KW - Interleukin-1β

KW - Phosphodiesterase

KW - PKA

KW - Rolipram

KW - TBI

KW - TNF-α

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=35348940651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348940651&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2007.08.011

DO - 10.1016/j.expneurol.2007.08.011

M3 - Article

VL - 208

SP - 145

EP - 158

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 1

ER -